• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

医学遗传学家的角色与职责。

Roles and responsibilities of a medical geneticist.

作者信息

Rubinstein Wendy S

机构信息

Evanston Northwestern Healthcare Center for Medical Genetics, Evanston, IL 60201, USA.

出版信息

Fam Cancer. 2008;7(1):5-14. doi: 10.1007/s10689-007-9148-6. Epub 2007 Jul 12.

DOI:10.1007/s10689-007-9148-6
PMID:17624600
Abstract

Medical geneticists must generate a differential diagnosis, practice evidence-based medicine, and apply ethical, legal, and social issue (ELSI) principles in the clinical setting. Several clinical scenarios are presented which illustrate dilemmas in the cancer genetics setting. These include the differential diagnosis of breast and gastric cancer, and the predicament posed by the need to practice evidence-based medicine in light of limitations in the medical genetics literature, which may mean recommending prophylactic surgery. Also discussed are three BRCA1/2 genetic testing scenarios which illustrate the difficulty of knowing where to "draw the line", i.e., when to offer testing and what level of testing to pursue. Decision-making about BRCA1/2 gene testing including Ashkenazi Jewish founder mutation testing, comprehensive reflex testing, and expedited testing, is explored. The duty to recontact as standard of care evolves requires that medical geneticists determine how to prospectively set expectations with patients as well as to decide which situations require recontact and to determine how to systematically do so. The case of patient recontact regarding new mutation detection techniques with improved sensitivity, e.g., BART testing which is based on the ability to detect large BRCA1/2 rearrangements, is discussed. General principles are highlighted so that these specific cases can be extrapolated to other genes and hereditary conditions by medical geneticists, genetic counselors, and others practicing in the field of cancer genetics.

摘要

医学遗传学家必须做出鉴别诊断,践行循证医学,并在临床环境中应用伦理、法律和社会问题(ELSI)原则。本文介绍了几种临床案例,阐述了癌症遗传学领域的困境。这些案例包括乳腺癌和胃癌的鉴别诊断,以及鉴于医学遗传学文献的局限性而在践行循证医学时所面临的困境,这可能意味着推荐预防性手术。文中还讨论了三种BRCA1/2基因检测案例,这些案例说明了确定“界限”的困难,即何时提供检测以及进行何种程度的检测。探讨了关于BRCA1/2基因检测的决策,包括阿什肯纳兹犹太人群体始祖突变检测、全面反射检测和快速检测。随着作为医疗标准的再次联系义务的发展,医学遗传学家需要确定如何前瞻性地为患者设定期望,以及决定哪些情况需要再次联系并确定如何系统地进行。文中讨论了与患者再次联系以告知新的具有更高灵敏度的突变检测技术的情况,例如基于检测BRCA1/2大片段重排能力的BART检测。文中强调了一般原则,以便医学遗传学家、遗传咨询师以及癌症遗传学领域的其他从业者能够将这些具体案例推广到其他基因和遗传性疾病。

相似文献

1
Roles and responsibilities of a medical geneticist.医学遗传学家的角色与职责。
Fam Cancer. 2008;7(1):5-14. doi: 10.1007/s10689-007-9148-6. Epub 2007 Jul 12.
2
Recontact practices of cancer genetic counselors and an exploration of professional, legal, and ethical duty.癌症遗传咨询师的再次接触实践以及对专业、法律和道德责任的探讨。
J Genet Couns. 2019 Aug;28(4):836-846. doi: 10.1002/jgc4.1126. Epub 2019 May 6.
3
Categorizing genetic tests to identify their ethical, legal, and social implications.对基因检测进行分类,以识别其伦理、法律和社会影响。
Am J Med Genet. 2001 Fall;106(3):233-40. doi: 10.1002/ajmg.10011.
4
Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.BRCA1/2 和 Lynch 综合征患者缺乏遗传咨询和检测转诊:基于 240134 次就诊和 134652 次基因检测的全国性研究。
Breast Cancer Res Treat. 2013 Aug;141(1):135-44. doi: 10.1007/s10549-013-2669-9. Epub 2013 Aug 24.
5
Hereditary breast-ovarian cancer: clinical findings and medical management.遗传性乳腺癌-卵巢癌:临床发现与医学管理
Plast Surg Nurs. 2007 Jul-Sep;27(3):124-7. doi: 10.1097/01.PSN.0000290280.48197.e7.
6
Hereditary breast cancer syndromes and clinical implications.遗传性乳腺癌综合征及其临床意义。
J Plast Reconstr Aesthet Surg. 2009 Feb;62(2):181-9. doi: 10.1016/j.bjps.2008.07.012. Epub 2008 Nov 21.
7
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.BRCAPRO验证、BRCA1/BRCA2基因检测的敏感性以及其他乳腺癌易感基因的患病率。
J Clin Oncol. 2002 Jun 1;20(11):2701-12. doi: 10.1200/JCO.2002.05.121.
8
Genetic testing for familial breast cancer--ethical questions concerning individual rights and social responsibility.家族性乳腺癌的基因检测——关于个人权利和社会责任的伦理问题。
Dis Markers. 1999 Oct;15(1-3):136-8. doi: 10.1155/1999/579421.
9
Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome.遗传性乳腺癌卵巢癌综合征的个体化预防与治疗管理
Nat Clin Pract Oncol. 2007 Oct;4(10):578-90. doi: 10.1038/ncponc0930.
10
Beyond BRCA1 and BRCA2.超越BRCA1和BRCA2。
Curr Probl Cancer. 2014 Nov-Dec;38(6):235-48. doi: 10.1016/j.currproblcancer.2014.10.004. Epub 2014 Nov 1.

引用本文的文献

1
GENETIC DUTIES.遗传职责。
William Mary Law Rev. 2020 Oct;62(1):143-211.
2
Recontacting in clinical practice: the views and expectations of patients in the United Kingdom.临床实践中的再次联系:英国患者的观点与期望
Eur J Hum Genet. 2017 Oct;25(10):1106-1112. doi: 10.1038/ejhg.2017.122. Epub 2017 Aug 2.
3
Recontacting in clinical practice: an investigation of the views of healthcare professionals and clinical scientists in the United Kingdom.临床实践中的再次联系:对英国医疗保健专业人员和临床科学家观点的调查。

本文引用的文献

1
The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features.阿什肯纳兹犹太裔结直肠癌患者中I1307K APC基因多态性:临床与病理特征
Cancer Genet Cytogenet. 2006 Aug;169(1):33-8. doi: 10.1016/j.cancergencyto.2006.03.007.
2
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.乳腺癌高危家族中BRCA1、BRCA2、CHEK2和TP53的突变谱。
JAMA. 2006 Mar 22;295(12):1379-88. doi: 10.1001/jama.295.12.1379.
3
Practicing medicine at the front lines of the genomic revolution.
Eur J Hum Genet. 2017 Feb;25(3):275-279. doi: 10.1038/ejhg.2016.188. Epub 2017 Jan 4.
4
Challenges for providing genetic counselling in Colombian genetic clinics: the viewpoint of the physicians providing genetic consultations.哥伦比亚基因诊所提供遗传咨询面临的挑战:提供遗传咨询的医生的观点。
J Community Genet. 2015 Jul;6(3):301-11. doi: 10.1007/s12687-015-0237-1. Epub 2015 Jun 19.
5
Family physicians' management of genetic aspects of a cardiac disease: a scenario-based study from slovenia.家庭医生对心脏病遗传方面的管理:一项来自斯洛文尼亚的基于案例的研究。
Balkan J Med Genet. 2014 Dec 11;17(1):15-22. doi: 10.2478/bjmg-2014-0020. eCollection 2014 Jun.
6
Is there a duty to recontact in light of new genetic technologies? A systematic review of the literature.鉴于新的基因技术,是否有再次联系的义务?文献系统综述。
Genet Med. 2015 Aug;17(8):668-78. doi: 10.1038/gim.2014.173. Epub 2014 Dec 11.
7
BRCA sequencing and large rearrangement testing in young Black women with breast cancer.年轻黑人乳腺癌女性的BRCA基因测序与大片段重排检测
J Community Genet. 2014 Apr;5(2):157-65. doi: 10.1007/s12687-013-0166-9. Epub 2013 Aug 29.
8
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers.犹太裔 BRCA1/2 基因突变携带者的乳腺癌和卵巢癌风险与降低风险。
J Clin Oncol. 2012 Apr 20;30(12):1321-8. doi: 10.1200/JCO.2011.37.8133. Epub 2012 Mar 19.
9
Detection of BRCA1 and BRCA2 Ashkenazi Jewish founder mutations in formalin-fixed paraffin-embedded tissues using conventional PCR and heteroduplex/amplicon size differences.采用常规 PCR 和异源双链体/扩增子大小差异检测福尔马林固定石蜡包埋组织中的 BRCA1 和 BRCA2 阿什肯纳兹犹太裔突变体。
J Mol Diagn. 2010 Jan;12(1):20-6. doi: 10.2353/jmoldx.2010.090023. Epub 2009 Dec 3.
在基因组革命的前沿从事医学实践。
Arch Intern Med. 2005 Sep 12;165(16):1815-7. doi: 10.1001/archinte.165.16.1815.
4
Gastric cancer: new genetic developments.胃癌:新的遗传学进展
J Surg Oncol. 2005 Jun 1;90(3):114-33; discussion 133. doi: 10.1002/jso.20214.
5
BRCA1 and BRCA2: 1994 and beyond.乳腺癌1号基因(BRCA1)和乳腺癌2号基因(BRCA2):1994年及以后
Nat Rev Cancer. 2004 Sep;4(9):665-76. doi: 10.1038/nrc1431.
6
Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.BRCA1/BRCA2咨询与检测对新诊断乳腺癌患者的影响。
J Clin Oncol. 2004 May 15;22(10):1823-9. doi: 10.1200/JCO.2004.04.086. Epub 2004 Apr 5.
7
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.在一项风险评估项目中确定的BRCA1突变携带者的癌症风险估计。
J Natl Cancer Inst. 2002 Sep 18;94(18):1365-72. doi: 10.1093/jnci/94.18.1365.
8
Cancer Incidence in BRCA1 mutation carriers.携带BRCA1基因突变者的癌症发病率。
J Natl Cancer Inst. 2002 Sep 18;94(18):1358-65. doi: 10.1093/jnci/94.18.1358.
9
Mathematical modeling for breast cancer risk assessment. State of the art and role in medicine.
Oncology (Williston Park). 2002 Aug;16(8):1082-94; discussion 1094, 1097-9.
10
Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families.高危阿什肯纳兹乳腺癌和卵巢癌家族中非始祖BRCA1和BRCA2突变的发生率。
J Med Genet. 2002 Aug;39(8):611-4. doi: 10.1136/jmg.39.8.611.